December 9, 2017Open Access

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Key Points

Key points are not available for this paper at this time.

Abstract

Over the next 5 years, some of these regimens are expected to provide potential new treatment options for patients with NASH/NAFLD. (Hepatology 2018;68:361-371).

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper

Cite This Study

Younossi et al. (Sat,) studied this question.

synapsesocial.com/papers/69dab4230f32475823a3d954 https://doi.org/https://doi.org/10.1002/hep.29724

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Mallory body—A disease-associated type of sequestosome2002 · 137 citations
2NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel.1991 · 496 citations
3A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C†2007 · 300 citations
4Gastrointestinal Surgery for Severe Obesity1991 · 2,167 citations
5Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review2011 · 523 citations

KI fragen

Bookmark

View Full Paper